Patrick Temple-West

archived 11 Sep 2025 19:07:31 UTC
archive.today
webpage capture
Saved from11 Sep 2025 19:07:31 UTC
All snapshotsfrom host www.ft.com
WebpageScreenshot
sharedownload .zipreport bug or abuseBuy me a coffee
close
short link
long link
markdown
html code
wiki code
Accessibility helpSkip to navigationSkip to contentSkip to footer
  • Sign In
  • Subscribe
Open side navigation menu Open search bar
Subscribe Sign In

Popular Searches

  • What is the latest news on the UK economy?
  • Western support for Ukraine
  • How will AI be regulated?
  • UK inflation vs the world
  • How will the UK economy fare in 2024?
  • Home
  • World
    Sections
    • World Home
    • Middle East war
    • Global Economy
    • UK
    • US
    • China
    • Africa
    • Asia Pacific
    • Emerging Markets
    • Europe
    • War in Ukraine
    • Americas
    • Middle East & North Africa
    Most Read
    • FBI releases images of ‘person of interest’ in Charlie Kirk shooting
    • Peter Mandelson sacked as UK ambassador to US over Epstein links
    • Trump ally Charlie Kirk assassinated in Utah
    • Charlie Kirk’s killing and the ‘despicable violence’ of US politics
    • US inflation rises to 2.9% in August
  • US
    Sections
    • US Home
    • US Economy
    • US Companies
    • US Politics & Policy
    Most Read
    • FBI releases images of ‘person of interest’ in Charlie Kirk shooting
    • Peter Mandelson sacked as UK ambassador to US over Epstein links
    • Trump ally Charlie Kirk assassinated in Utah
    • Charlie Kirk’s killing and the ‘despicable violence’ of US politics
    • US inflation rises to 2.9% in August
  • Companies
    Sections
    • Companies Home
    • Energy
    • Financials
    • Health
    • Industrials
    • Media
    • Professional Services
    • Retail & Consumer
    • Tech Sector
    • Telecoms
    • Transport
    Most Read
    • Sotheby’s annual loss more than doubles to $248mn
    • Aspiration Partners’ collapse leaves trail of losses from Hollywood to Wall Street
    • Billionaire John Caudwell calls for gambling tax to combat ‘mayhem in society’
    • VW vows to defend Europe crown in fightback against Chinese EVs
    • How Oracle’s Larry Ellison rode the AI ‘tsunami’
  • Tech
    Sections
    • Tech Home
    • Artificial intelligence
    • Semiconductors
    • Cyber Security
    • Social Media
    Most Read
    • Aspiration Partners’ collapse leaves trail of losses from Hollywood to Wall Street
    • How Oracle’s Larry Ellison rode the AI ‘tsunami’
    • Larry Ellison’s personal fortune soars on back of Oracle’s share price surge
    • AI can’t write good analyst research yet, says analyst
    • Mistral is stirring up a storm in European tech
  • Markets
    Sections
    • Markets Home
    • Alphaville
    • Markets Data
    • Crypto
    • Capital Markets
    • Commodities
    • Currencies
    • Equities
    • Monetary Policy Radar
    • Wealth Management
    • Moral Money
    • ETF Hub
    • Fund Management
    • Trading
    Most Read
    • Aspiration Partners’ collapse leaves trail of losses from Hollywood to Wall Street
    • Why the bond ‘rout’ might not be what it seems
    • Trump’s CFTC pick claims Winklevoss twins meddled with confirmation
    • How worried should we be about the crypto crush?
    • SEC chief threatens ban on European accounting rules over sustainability
  • Climate
  • Opinion
    Sections
    • Opinion Home
    • Columnists
    • The FT View
    • The Big Read
    • Lex
    • Obituaries
    • Letters
    Most Read
    • Exit Mandelson — leaving questions about Downing Street’s judgment
    • Starmer is still captive to Labour’s contradictions
    • Japan confronts the increased price of US friendship
    • Farage’s self-defeating embrace of Trump
    • The remorseless rule of my fitness tracker
  • Lex
  • Work & Careers
    Sections
    • Work & Careers Home
    • Business School Rankings
    • Business Education
    • Europe's Start-Up Hubs
    • Entrepreneurship
    • Recruitment
    • Business Books
    • Business Travel
    • Working It
    Most Read
    • The red flags lurking in job advertisements
    • Pogust Goodhead suffers lawyer revolt over alleged hedge fund meddling
    • Five of Frankfurt’s must-try culinary specialities
    • Why AI is sending hiring practices backwards
  • Life & Arts
    Sections
    • Life & Arts Home
    • Arts
    • Books
    • Food & Drink
    • FT Magazine
    • House & Home
    • Style
    • Puzzles
    • Travel
    • FT Globetrotter
    Most Read
    • The remorseless rule of my fitness tracker
    • Spinal Tap II: The End Continues has comedy riffs, sweetness and too much perspective
    • How Maga rewrote the Little Red Book
    • What We Can Know — Ian McEwan’s most entertaining novel in years
    • How to Save the Internet by Nick Clegg — big but not radical ideas
  • HTSI
Menu Search
  • Home
  • World
  • US
  • Companies
  • Tech
  • Markets
  • Climate
  • Opinion
  • Lex
  • Work & Careers
  • Life & Arts
  • HTSI
Financial Times
Subscribe Sign In

Popular Searches

  • What is the latest news on the UK economy?
  • Western support for Ukraine
  • How will AI be regulated?
  • UK inflation vs the world
  • How will the UK economy fare in 2024?

Patrick Temple-West

US pharmaceutical correspondent

Patrick Temple-West covers pharmaceutical and healthcare companies for the Financial Times in New York. He previously covered corporate governance, with a focus on ESG and executive pay.
Before he joined the FT, he covered the US Securities and Exchange Commission for Politico and tax policy for Reuters. He started his career amid the 2008 financial crisis covering economics and municipal bonds.
Email Patrick Temple-West @temple_west  on Twitter (link opens in a new browser window)
  • September 10 2025
    Medical science
    Merck slams UK as it scraps £1bn London drug research centre
    US company says country is ‘not internationally competitive’ and lays off 125 staff
    Belgrove House under construction in King’s Cross, with pedestrians and traffic in the foreground.
  • September 9 2025
    Pharmaceuticals sector
    US regulators target drugmakers over ‘misleading advertisements’
    Trump administration sends cease-and-desist letters to pharma groups and social media influencers
    The New York Stock Exchange with a Hims & Hers Health banner on the outside
  • September 7 2025
    Healthcare
    Americans face biggest increase in health insurance costs in 15 years
    Rising premiums add to pressure on households already feeling pinch from high price of goods
    Pages from the United Healthcare website shown on a computer screen, featuring the company logo and navigation menu
  • September 5 2025
    Kenvue
    Tylenol maker’s shares sink on Kennedy report linking painkiller to autism
    Company says key ingredient acetaminophen has been approved for use by US regulators
    Tylenol on the shelf of a supermarket in New York
  • September 4 2025
    US politics & policy
    Robert Kennedy grilled over vaccine scepticism in fiery US Senate hearing
    Trump officials defend health secretary after sharp questioning from Republican and Democratic lawmakers
    Robert F. Kennedy Jr. speaks with hands clasped while testifying at a Senate Finance Committee hearing on healthcare.
  • Advertisement
  • August 29 2025
    Pharmaceuticals sector
    US regulator approves at-home Alzheimer’s drug from Eisai and Biogen
    Go ahead for Leqembi shot by Food and Drug Administration could help revive two companies’ sluggish sales
    Two vials and two boxes of LEQEMBI (lecanemab-irmb) injection, an Alzheimer's drug, are displayed
  • August 28 2025
    Centers for Disease Control and Prevention
    US health agency leadership turmoil gives Kennedy the upper hand
    Battle for control of the CDC follows rising tension over health secretary’s position on vaccines
    Robert F Kennedy Jr at a Senate committee hearing in May
  • August 28 2025
    Centers for Disease Control and Prevention
    White House says it fired US health agency chief after her refusal to step down
    CDC director Susan Monarez’s lawyers earlier said she had not been notified by the administration of her removal
    Susan Monarez during her Senate confirmation hearing
  • August 26 2025
    Eli Lilly & Co
    Eli Lilly’s weight-loss pill meets target in key diabetes trial
    Results from US pharma group show oral drug reduced body weight by 10.5% on average
    The Eli Lilly logo in red script on a wall at the company's Digital Health Innovation Hub in Singapore, with a person entering the facility
  • August 18 2025
    Novo Nordisk AS
    Novo Nordisk halves US price of Ozempic
    Danish group’s shares rise after it cuts cost for blockbuster diabetes and weight-loss drug for patients without insurance
    Several blue Ozempic pens are lined up on a production line, ready for packaging
  • August 15 2025
    Pharmaceuticals sector
    Weight-loss weariness and Trump threats wipe $250bn off Novo Nordisk and Eli Lilly
    Trump’s push for price cuts and tariffs weighs on ‘obesity franchises’, which have missed out on equity market’s rise
    Wegovy injection pens labelled with different dosages displayed upright in a clear holder at a news conference.
  • Advertisement
  • August 15 2025
    UnitedHealth Group Inc
    UnitedHealth shares jump after Buffett’s Berkshire takes stake
    Troubled healthcare group has been one of the worst performers on the S&P 500 this year
    A computer screen shows multiple pages from the United Healthcare website, including the logo and navigation options.
  • August 11 2025
    US Food & Drug Administration
    Return of FDA official targeted by Trump allies hits biotech shares
    Food and Drug Administration reinstates Vinay Prasad who left agency in July after social media campaign
    Vinay Prasad smiles in a portrait with part of a US flag in the background
  • August 8 2025
    News in-depthUS politics & policy
    ‘How’s the gout?’: US business titans seek to woo Trump with flattery
    Tim Cook and Brian Moynihan are among bosses determined to keep the president happy
    Brian Moynihan, Tim Cook and Jensen Huang
  • August 5 2025
    Pfizer Inc
    Pfizer predicts higher profit amid cost cuts and pricing pressure from Trump
    Drugmaker says it is on track to make $7.2bn in savings by the end of 2027
    Workers at a Pfizer manufacturing site
  • August 5 2025
    Drug prices
    Sandoz targets 70% price cut for weight-loss drugs in Canada
    Generic drugmaker is preparing cheaper alternatives for when patents expire in the country next year
    Richard Saynor, chief executive officer of Sandoz
  • Advertisement
  • July 31 2025
    Drug prices
    Trump demands drug companies lower prices before end of September
    US president threatens to ‘deploy every tool in our arsenal’ to protect Americans from ‘abusive drug prices’
    Medications are stored on shelves at a pharmacy in Los Angeles, California
  • July 29 2025
    UnitedHealth Group Inc
    UnitedHealth says it faces $1.6bn in potential settlement costs
    US health and insurance company profits shrink as patient care costs surge after difficult start to 2025
    UnitedHealthcare’s logo on a sign outside its office in Cypress, California
  • July 29 2025
    Merck & Co Inc
    Merck hit by sharp decline in HPV vaccine sales in China
    US drugmaker reports 17% fall in net income to $4.4bn in second quarter
    Medical workers inject Chinese bivalent HPV vaccine into school girls at a community health service centre
  • July 29 2025
    US healthcare reform
    Arkansas governor leads charge to break up US pharmacy companies
    Effort by Sarah Huckabee Sanders could have broad implications for America’s healthcare system
    Sarah Sanders
  • July 24 2025
    UnitedHealth Group Inc
    UnitedHealth acknowledges criminal DoJ investigation
    Healthcare group had contradicted media report in May alleging existence of probe into Medicare billing
    UnitedHealthcare building
  • July 23 2025
    FT News Briefing podcast10 min listen
    Big Pharma’s China gamble
    Despite looming tariffs, global pharma companies rely on Chinese biotech
  • July 22 2025
    Pharmaceuticals sector
    Big Pharma is increasingly reliant on Chinese biotech advances
    Drugmakers increasingly rely on medicines made in China even as the country faces Trump’s tariffs
    A technician sorts mouse embryos under a microscope inside a laboratory at a Cyagen Biosciences Inc. facility in Taicang, Jiangsu province, China
  • July 18 2025
    World Health Organization
    US rejects WHO pandemic response measures
    Decision could hamper global co-operation for future health crises
    US health secretary Robert Kennedy Jr
  • July 16 2025
    Pharmaceuticals sector
    J&J shares jump after forecasting sales boost and milder tariff impact
    Group reports strong revenues and ‘favourable foreign exchange’ rates in second quarter
    People walk by a Johnson & Johnson banner displayed on the front of the New York Stock Exchange
Previous page1Next page

Useful links

Support

View Site TipsHelp CentreContact UsAbout UsAccessibilitymyFT TourCareersSuppliers

Legal & Privacy

Terms & ConditionsPrivacy PolicyCookie PolicyManage CookiesCopyrightSlavery Statement & Policies

Services

Share News Tips SecurelyIndividual SubscriptionsProfessional SubscriptionsRepublishingExecutive Job SearchAdvertise with the FTFollow the FT on XFT ChannelsFT Schools

Tools

PortfolioFT AppFT Digital EditionFT EditAlerts HubBusiness School RankingsSubscription ManagerNews feedNewslettersCurrency Converter

Community & Events

FT Live EventsFT ForumsFT Leaders Academy

More from the FT Group

Markets data delayed by at least 15 minutes. © THE FINANCIAL TIMES LTD 2025. FT and ‘Financial Times’ are trademarks of The Financial Times Ltd.
The Financial Times and its journalism are subject to a self-regulation regime under the FT Editorial Code of Practice.
Edition:International
UK
Subscribe for full access

Top sections

  • Home
  • World
    • Middle East war
    • Global Economy
    • UK
    • US
    • China
    • Africa
    • Asia Pacific
    • Emerging Markets
    • Europe
    • War in Ukraine
    • Americas
    • Middle East & North Africa
  • US
    • US Economy
    • US Companies
    • US Politics & Policy
  • Companies
    • Energy
    • Financials
    • Health
    • Industrials
    • Media
    • Professional Services
    • Retail & Consumer
    • Tech Sector
    • Telecoms
    • Transport
  • Tech
    • Artificial intelligence
    • Semiconductors
    • Cyber Security
    • Social Media
  • Markets
    • Alphaville
    • Markets Data
    • Crypto
    • Capital Markets
    • Commodities
    • Currencies
    • Equities
    • Monetary Policy Radar
    • Wealth Management
    • Moral Money
    • ETF Hub
    • Fund Management
    • Trading
  • Climate
  • Opinion
    • Columnists
    • The FT View
    • The Big Read
    • Lex
    • Obituaries
    • Letters
  • Lex
  • Work & Careers
    • Business School Rankings
    • Business Education
    • Europe's Start-Up Hubs
    • Entrepreneurship
    • Recruitment
    • Business Books
    • Business Travel
    • Working It
  • Life & Arts
    • Arts
    • Books
    • Food & Drink
    • FT Magazine
    • House & Home
    • Style
    • Puzzles
    • Travel
    • FT Globetrotter
  • Personal Finance
    • Property & Mortgages
    • Investments
    • Pensions
    • Tax
    • Banking & Savings
    • Advice & Comment
  • HTSI
  • Special Reports

FT recommends

  • Alphaville
  • FT Edit
  • Lunch with the FT
  • FT Globetrotter
  • #techAsia
  • Moral Money
  • Visual and data journalism
  • Newsletters
  • Video
  • Podcasts
  • News feed
  • FT Schools
  • FT Live Events
  • FT Forums
  • FT Leaders Academy
  • Portfolio
  • FT Digital Edition
  • Crossword
  • Our Apps
  • Help Centre
  • Subscribe
  • Sign In
0%
 
10%
 
20%
 
30%
 
40%
 
50%
 
60%
 
70%
 
80%
 
90%
 
100%